Cogstate (FRA:C4B) Other Financing: €-0.09 Mil (TTM As of Dec. 2025)


FRA:C4B Cogstate Ltd FRA:C4B
69 GF Score
Price €1.68
GF Value €1.35
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cogstate Other Financing?

Cogstate FRA:C4B +1.82% 69 Other Financing is €-0.09 Mil as of Dec. 2025. GuruFocus rates FRA:C4B with a GF Score™ of 69/100 and a GF Value™ of €1.35 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Cogstate's Other Financing for the six months ended in Dec. 2025 was €-0.05 Mil.

Cogstate's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.09 Mil.

Cogstate Other Financing Historical Data

* Premium members only.

The historical data trend for Cogstate's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogstate Other Financing Chart

Cogstate Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 -0.47 -0.23 -0.10

Cogstate Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.07 -0.05 -0.05 -0.05
FRA:C4B
69GF Score
Cogstate Ltd FRA:C4B
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogstate Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-0.09 Mil mean?
Cogstate (FRA:C4B) has a Other Financing of €-0.09 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cogstate and its competitors.
Is Cogstate's Other Financing too high?
Cogstate's current Other Financing is €-0.09 Mil. Overall, Cogstate has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Other Financing compare to VEEV and BTSG?
Cogstate's Other Financing of €-0.09 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Healthcare Providers & Services company?
A good Other Financing depends on the Healthcare Providers & Services industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cogstate and its competitors. Cogstate's current Other Financing is €-0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (FRA:C4B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.35, compared to a current price of €1.68 — trading 24.4% above its estimated fair value. The current Other Financing is €-0.09 Mil. Cogstate's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Cogstate (FRA:C4B), the current Other Financing is €-0.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cogstate (FRA:C4B) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of €1.68 is trading 24.4% above its estimated GF Value™ of €1.35. GuruFocus considers Cogstate to be Modestly Overvalued.

Key valuation signals for FRA:C4B:

  • Other Financing: €-0.09 Mil
  • GF Value™: €1.35 vs. price of €1.68 (24.4% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the FRA:C4B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cogstate Business Description

Other Exchanges COGZF:USACGS:Australia
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
69GF Score

Get the complete analysis for FRA:C4B

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.68
Price
€1.35
GF Value